113 related articles for article (PubMed ID: 17875793)
41. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
[TBL] [Abstract][Full Text] [Related]
42. Effect of metal ions on high-affinity binding of pseudosubstrate inhibitors to PKA.
Zimmermann B; Schweinsberg S; Drewianka S; Herberg FW
Biochem J; 2008 Jul; 413(1):93-101. PubMed ID: 18373497
[TBL] [Abstract][Full Text] [Related]
43. Proteome-wide prediction of PKA phosphorylation sites in eukaryotic kingdom.
Gao X; Jin C; Ren J; Yao X; Xue Y
Genomics; 2008 Dec; 92(6):457-63. PubMed ID: 18817865
[TBL] [Abstract][Full Text] [Related]
44. Molecular docking for substrate identification: the short-chain dehydrogenases/reductases.
Favia AD; Nobeli I; Glaser F; Thornton JM
J Mol Biol; 2008 Jan; 375(3):855-74. PubMed ID: 18036612
[TBL] [Abstract][Full Text] [Related]
45. Modelling and mutational evidence identify the substrate binding site and functional elements in APC amino acid transporters.
Vangelatos I; Vlachakis D; Sophianopoulou V; Diallinas G
Mol Membr Biol; 2009 Aug; 26(5):356-70. PubMed ID: 19670073
[TBL] [Abstract][Full Text] [Related]
46. Modulation of cardiac function by A-kinase anchoring proteins.
Diviani D
Curr Opin Pharmacol; 2008 Apr; 8(2):166-73. PubMed ID: 18165153
[TBL] [Abstract][Full Text] [Related]
47. In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets.
Visintin M; Melchionna T; Cannistraci I; Cattaneo A
J Biotechnol; 2008 May; 135(1):1-15. PubMed ID: 18395925
[TBL] [Abstract][Full Text] [Related]
48. Downstream processing of monoclonal antibodies--application of platform approaches.
Shukla AA; Hubbard B; Tressel T; Guhan S; Low D
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):28-39. PubMed ID: 17046339
[TBL] [Abstract][Full Text] [Related]
49. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
[TBL] [Abstract][Full Text] [Related]
50. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1.
Day CL; Smits C; Fan FC; Lee EF; Fairlie WD; Hinds MG
J Mol Biol; 2008 Jul; 380(5):958-71. PubMed ID: 18589438
[TBL] [Abstract][Full Text] [Related]
51. Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1.
Charles CH; Luo GX; Kohlstaedt LA; Morantte IG; Gorfain E; Cao L; Williams JH; Fang F
Antimicrob Agents Chemother; 2003 May; 47(5):1503-8. PubMed ID: 12709314
[TBL] [Abstract][Full Text] [Related]
52. Developing a manufacturing process and analyses for a recombinant protein drug.
Florin-Robertsson E
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):149-50. PubMed ID: 15119032
[No Abstract] [Full Text] [Related]
53. Advances and challenges in developing cytokine fusion proteins as improved therapeutics.
Chang CH; Gupta P; Goldenberg DM
Expert Opin Drug Discov; 2009 Feb; 4(2):181-94. PubMed ID: 23480515
[TBL] [Abstract][Full Text] [Related]
54. Mansfield in the dock.
Nature; 1970 Aug; 227(5257):426. PubMed ID: 16057992
[No Abstract] [Full Text] [Related]
55. The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures.
Rossi EA; Goldenberg DM; Chang CH
Bioconjug Chem; 2012 Mar; 23(3):309-23. PubMed ID: 22168393
[TBL] [Abstract][Full Text] [Related]
56. The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers.
van Diest E; Nicolasen MJT; Kramer L; Zheng J; Hernández-López P; Beringer DX; Kuball J
Front Immunol; 2022; 13():1052090. PubMed ID: 36685546
[TBL] [Abstract][Full Text] [Related]
57. Modular Assembly of Phosphite Dehydrogenase and Phenylacetone Monooxygenase for Tuning Cofactor Regeneration.
Purwani NN; Martin C; Savino S; Fraaije MW
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204515
[TBL] [Abstract][Full Text] [Related]
58. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
Goldenberg DM; Stein R; Sharkey RM
Oncotarget; 2018 Jun; 9(48):28989-29006. PubMed ID: 29989029
[TBL] [Abstract][Full Text] [Related]
59. An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.
Jin J; Park G; Park JB; Kim S; Kim H; Chung J
Exp Mol Med; 2018 May; 50(5):1-14. PubMed ID: 29795377
[TBL] [Abstract][Full Text] [Related]
60. Bispecific antibodies: design, therapy, perspectives.
Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
